Shilpa Medicare Ltd

Profit before exceptional items and tax stood at Rs 43.35 crore in Q4 FY25, up 100.88% from Rs 21.58 crore posted in the corresponding quarter previous year. The firm reported exceptional items of Rs 28.08 crore during the quarter. EBITDA jumped 15% to Rs 84 crore in Q4 FY25 from Rs 73 crore in Q4 FY24. EBITDA margin remained constant at 25% in Q4 FY25 compared to Q4 FY24. Total expenses were up by 9.12% year on year to Rs 297.32 crore in the quarter ended 31 March 2025. The cost of materials consumed stood at Rs 85.14 crore (down 15.83% YoY), while employee benefits expense was at Rs 70.93 crore (up 6.72% YoY). On a full-year basis, the company's consolidated net profit surged 145.65% to Rs 78.29 crore on an 11.70% jump in revenue from operations to Rs 1,286.41 crore in FY25 over FY24. Vishnukant Bhutada, managing director of Shilpa Medicare, said, 'FY25 performance reflects our pursuit of a differentiated business model enabling us to grow with improved profitability. In FY25, Shilpa Medicare has emerged stronger, turning years of strategic investments and relentless perseverance into remarkable achievements in differentiated initiatives like the launch of two NDAs in US market, filing of transdermal patch product in EU, SEC clearance of Nor-UDCA in India and OLC filing by our partner with US FDA. Our unwavering commitment to innovation and R&D has borne fruit, with a significant breakthrough in out-licensing our flagship product'recombinant human albumin'for commercialization across EU region in strategic partnership with Orion Corporation. Besides this, we also saw a very successful year on the regulatory front, as we received EIR for our API Unit 1, along with EU GMP certifications for our FDF Unit 6 (having ODF & TDP manufacturing capabilities) and for our Biologics unit. I believe this will help in enabling us to further scale up our biologics CDMO platform and give us the opportunity to monetize our biosimilar pipeline for large regulated markets. With asset utilization improvement across key verticals, we remain confident of delivering improved profitability in FY26. As we advance, we remain committed to leveraging our R&D strengths, regulatory compliance, and operational agility to create long-term value.' Meanwhile, the company's board has decided to pay a dividend of Rs 1 per equity share for FY 2024-2025. The final dividend, if approved by the members at the ensuing Annual General Meeting, shall be paid within the statutory timelines prescribed under applicable laws. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India.   Powered by Capital Market - Live

Shilpa Medicare announced that the Board of Directors of the Company at its meeting held on 26 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Shilpa Medicare declined 40.78% to Rs 14.51 crore in the quarter ended March 2025 as against Rs 24.50 crore during the previous quarter ended March 2024. Sales rose 13.41% to Rs 330.80 crore in the quarter ended March 2025 as against Rs 291.69 crore during the previous quarter ended March 2024. For the full year,net profit rose 145.65% to Rs 78.29 crore in the year ended March 2025 as against Rs 31.87 crore during the previous year ended March 2024. Sales rose 11.71% to Rs 1286.41 crore in the year ended March 2025 as against Rs 1151.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales330.80291.69 13 1286.411151.60 12 OPM %23.2123.97 -24.5520.82 - PBDT72.1548.21 50 263.41156.07 69 PBT43.3521.58 101 150.4148.20 212 NP14.5124.50 -41 78.2931.87 146 Powered by Capital Market - Live

Netweb Technologies India Ltd, Linde India Ltd, Vaibhav Global Ltd and ITD Cementation India Ltd are among the other gainers in the BSE's 'A' group today, 26 May 2025.Shilpa Medicare Ltd soared 9.96% to Rs 859.35 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 57518 shares were traded on the counter so far as against the average daily volumes of 11252 shares in the past one month. Netweb Technologies India Ltd surged 8.64% to Rs 1953. The stock was the second biggest gainer in 'A' group. On the BSE, 74595 shares were traded on the counter so far as against the average daily volumes of 81699 shares in the past one month. Linde India Ltd spiked 8.00% to Rs 7620.8. The stock was the third biggest gainer in 'A' group. On the BSE, 13043 shares were traded on the counter so far as against the average daily volumes of 2502 shares in the past one month. Vaibhav Global Ltd jumped 7.12% to Rs 258.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 31297 shares were traded on the counter so far as against the average daily volumes of 35385 shares in the past one month. ITD Cementation India Ltd added 6.94% to Rs 709.6. The stock was the fifth biggest gainer in 'A' group. On the BSE, 92566 shares were traded on the counter so far as against the average daily volumes of 83768 shares in the past one month. Powered by Capital Market - Live

Under this strategic agreement, Orion Corporation will serve as the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe. As part of the deal, Shilpa is entitled to receive development and regulatory milestone payments from Orion. Shilpa has been investing in the development of this novel product for approximately eight years, including the establishment of a large-scale fermentation facility designed to manufacture recombinant human albumin. This facility aims to meet the global demand for this life-saving drug. The collaboration with Orion marks a major milestone in Shilpa's expansion into the global biosimilar and biopharmaceutical markets, leveraging Orion's strong regional presence, regulatory expertise, and established commercial infrastructure. The firm stated that Orion Corporation is not a related party to the company, Shilpa Biocare (SBPL), or any of the promoter/promoter group/group companies. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications and as a critical component in vaccine and biologics manufacturing. Shilpa Medicare's recombinant human albumin is developed using a robust non-human expression system, ensuring high safety, scalability, and virus-free production, effectively addressing key limitations associated with human-derived albumin. This partnership reinforces both companies' commitment to advancing biotechnology-driven therapies and improving patient access to safer, sustainable, and next-generation biologics. Madhav Bhutada, Managing Director, Shilpa Biocare, said, 'partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental & manufacturing capabilities to bring recombinant human albumin to market. This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.' Satu Ahom'ki, EVP Generics and Consumer Health, Orion Corporation, said, 'We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product. Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.' Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year. Powered by Capital Market - Live

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

In an exchange filing, the company stated that the USFDA has classified the inspection outcome as voluntary action indicated (VAI). The inspection was conducted at the Unit-1 facility from 3 March to 7 March 2025. The official announcement was made on 14 May 2025, after market hours. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year. Powered by Capital Market - Live

Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product is around 203 M USD. Shilpa's product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). Varenicline Tablets are indicated for smoking cessation; it helps people to quit smoking. Powered by Capital Market - Live

Varenicline helps people quit smoking by blocking the effect of nicotine on the brain. Nicotine is a substance found in cigarettes and other tobacco products that makes smoking feel good. Varenicline blocks this good feeling and can help prevent cravings to smoke cigarettes. The total US market for varenicline products is around $203 million. Shilpa's product has been approved as a generic version of the innovator, Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year. Shares of Shilpa Medicare tumbled 3.64% to Rs 620.10 on the BSE. Powered by Capital Market - Live

BORUZU (Bortezomib for injection 3.5mg/1.4ml) is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma. It serves as a reference to the branded product Velcade, which is a lyophilized powder that requires reconstitution before use. The pharma major stated that BORUZU (bortezomib injection) is a new presentation of bortezomib designed for ready-to-use subcutaneous or intravenous (IV) administration. This ready-to-use oncology product reduces the compounding preparation steps typically required during administration. The product has already been granted a permanent J-code by the U.S. Centers for Medicare & Medicaid Services (CMS). Vishnukant Bhutada, managing director of Shilpa Medicare, said, 'This is the second NDA product being launched in the US market from our novel injectable portfolio demonstrates our capabilities and commitment to introduce pharmacy efficient solutions that enhance compliance and have the potential to reduce patient wait times. This development exemplifies Shilpa's constant endeavor to work towards introducing novel first of its kind pharmaceutical products that help improve the healthcare requirements of a large patient pool.' Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year. Powered by Capital Market - Live